Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab
Files
Publication date
2013-09
Authors
Ebbers, Hans C.
van Meer, Peter J K
Moors, Ellen
Mantel - Teeuwisse, Aukje
Leufkens, Bert
Schellekens, Huub
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Biosimilars have been available on the European market since 2006 and experience with their use is increasing. The next wave of biopharmaceuticals that are about to lose patent protection consists of more-complicated products, including many monoclonal antibodies. Guidance has been released on the particulars of a biosimilarity exercise involving these products. Considerable challenges exist to establish biosimilarity for anticancer products. An especially challenging product is bevacizumab (Avastin(®)). On the basis of data available for the innovator product (bevacizumab) we will discuss strengths and weaknesses of preclinical and clinical models and explore the application of novel endpoints to the biosimilar comparability exercise.
Keywords
Angiogenesis Inhibitors, Animals, Antibodies, Monoclonal, Humanized, Bevacizumab, Biosimilar Pharmaceuticals, Drug Evaluation, Preclinical, Humans, Patents as Topic, Patient Safety, Quality Control, Risk Assessment, Risk Factors, Therapeutic Equivalency, Taverne
Citation
Ebbers, H C, van Meer, P J K, Moors, E H M, Mantel-Teeuwisse, A K, Leufkens, H G M & Schellekens, H 2013, 'Measures of biosimilarity in monoclonal antibodies in oncology : the case of bevacizumab', Drug Discovery Today, vol. 18, no. 17-18, pp. 872-879. https://doi.org/10.1016/j.drudis.2013.05.004